116 patents
Page 2 of 6
Utility
Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy
14 Mar 23
Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs.
Roman Galetto, Agnès Gouble, Stéphanie Grosse, Cécile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
Filed: 13 May 13
Utility
New mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy
2 Mar 23
The present invention relates to engineered immune cells expressing new mesothelin (MLSN) specific chimeric antigen receptors (anti-mesothelin CAR) and their use in the treatment of solid tumors, particularly suited for allogeneic cell immunotherapy.
Cecile SCHIFFER-MANNIOUI, Philippe DUCHATEAU
Filed: 22 Dec 20
Utility
Methods for Engineering Highly Active T Cell for Immunotheraphy
23 Feb 23
The present invention relates to methods for developing engineered T-cells for immunotherapy and more specifically to methods for modifying T-cells by inactivating at immune checkpoint genes, preferably at least two selected from different pathways, to increase T-cell immune activity This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells.
Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cécile SCHIFFER-MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
Filed: 8 Apr 22
Utility
Methods for Engineering Allogeneic and Highly Active T Cell for Immunotheraphy
16 Feb 23
The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive.
Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cécile SCHIFFER-MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
Filed: 7 Apr 22
Utility
Large volume ex vivo electroporation method
14 Feb 23
An object of the invention is to provide an electroporation method for treating vesicles with exogenous material for insertion of the exogenous material into the vesicles which includes the steps of: a. retaining a suspension of the vesicles and the exogenous material in a treatment volume in a chamber which includes electrodes, wherein the chamber has a geometric factor (cm−1) defined by the quotient of the electrode gap squared (cm2) divided by the chamber volume (cm3), wherein the geometric factor is less than or equal to 0.1 cm−1, wherein the suspension of the vesicles and the exogenous material is in a medium which is adjusted such that the medium has conductivity in a range spanning 50 microSiemens/cm to 500 microSiemens/cm, wherein the suspension is enclosed in the chamber during treatment, and b. treating the suspension enclosed in the chamber with one or more pulsed electric fields.
Richard E Walters, Alan D King
Filed: 18 Apr 18
Utility
Mutant
14 Feb 23
Materials and methods are provided for making plants (e.g., Nicotiana varieties) that are suitable for producing therapeutic polypeptides suitable for administration to humans and animals, particularly by making TAL effector endonuclease-induced mutations in genes encoding xylosyltransferases and fucosyltransferases.
Luc Mathis, Daniel F. Voytas, Jin Li, Feng Zhang, Thomas Stoddard, Marc-Andre D'Aoust
Filed: 13 Nov 20
Utility
Method for making nicotiana plants with mutations in XylT and FucT alleles using rare-cutting endonucleases
17 Jan 23
Materials and methods are provided for making plants (e.g., Nicotiana varieties) that are suitable for producing therapeutic polypeptides suitable for administration to humans and animals, particularly by making TAL effector endonuclease-induced mutations in genes encoding xylosyltransferases and fucosyltransferases.
Luc Mathis, Daniel F. Voytas, Jin Li, Feng Zhang, Thomas Stoddard, Marc-Andre D'Aoust
Filed: 31 Oct 13
Utility
BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
15 Nov 22
The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a BCMA monoclonal antibody, conferring specific immunity against BCMA positive cells.
Roman Galetto
Filed: 8 May 19
Utility
Use of Pre T Alpha or Functional Variant Thereof for Expanding TCR Alpha Deficient T Cells
3 Nov 22
A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex.
Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
Filed: 24 Jun 22
Utility
Alfalfa with reduced lignin composition
25 Oct 22
Materials and methods for creating plants (e.g., alfalfa lines) with reduced lignin content and composition are provided herein, as are plants, plant parts, and plant cells generated by the methods provided herein.
Song Luo, Nicholas J. Baltes
Filed: 25 Apr 18
Utility
Sequential gene editing in primary immune cells
11 Oct 22
The invention pertains to the field of adaptive cell immunotherapy.
Jean-Pierre Cabaniols, Jean-Charles Epinat, Philippe Duchateau
Filed: 30 Jun 17
Utility
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
16 Aug 22
A method of expanding deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex.
Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
Filed: 22 Mar 19
Utility
Cellular Immunotherapy for Repetitive Administration
28 Jul 22
The present invention provides composition kits and methods for treating cancer in a human by immunotherapy using successive doses of CAR-T cells with no or reduced anamnestic immune reaction in one individual (P).
David SOURDIVE, Aymeric DUCLERT, Mathieu SIMON, Philippe DUCHATEAU, Alan Marc WILLIAMS, Laurent POIROT
Filed: 2 Jul 18
Utility
Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
21 Jun 22
The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy.
Philippe Duchateau, André Choulika, Laurent Poirot
Filed: 18 Feb 20
Utility
Use of Pre T Alpha or Functional Variant Thereof for Expanding TCR Alpha Deficient T Cells
9 Jun 22
A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex.
Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
Filed: 17 Feb 22
Utility
Methods for engineering highly active T cell for immunotherapy
26 Apr 22
The present invention relates to methods for developing engineered T-cells for immunotherapy and more specifically to methods for modifying T-cells by inactivating at immune checkpoint genes, preferably at least two selected from different pathways, to increase T-cell immune activity.
Roman Galetto, Agnes Gouble, Stephanie Grosse, Cécile Schiffer-Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
Filed: 13 May 14
Utility
Methods for altering amino acid content in plants through frameshift mutations
26 Apr 22
Materials and methods are provided for making plants with altered levels of amino acids, particularly by making controlled frameshift mutations in genes that are highly expressed in plant leaves or plant seeds.
Nicholas Baltes, Song Luo
Filed: 16 Nov 17
Utility
Methods for engineering allogeneic and highly active t cell for immunotherapy
19 Apr 22
The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive.
Roman Galetto, Agnes Gouble, Stephanie Grosse, Cécile Schiffer-Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
Filed: 13 May 14
Utility
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
15 Mar 22
A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex.
Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
Filed: 11 Mar 21
Utility
Inhibitory Chimeric Antigen Receptors
3 Feb 22
ARVIND RAJPAL, Shobha Chowdary Potluri, Laurent Poirot, Alexandre Juillerat, Thomas Charles Pertel, Donna Marie Stone, Barbra Johnson Sasu
Filed: 26 Jul 21